News >

Nivolumab/Cabiralizumab Combo Misses PFS Endpoint in Pancreatic Cancer

Gina Columbus
Published: Tuesday, Feb 18, 2020

Helen Collins, MD

Helen Collins, MD

The combination of nivolumab (Opdivo) and the investigational CSF-1R inhibitor cabiralizumab with and without chemotherapy did not improve progression-free survival (PFS) compared with chemotherapy alone in patients with advanced pancreatic cancer, missing the primary endpoint of a phase II trial (NCT03336216).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication